Paper40969260
Challenges and breakthroughs: current landscape and future prospects of CAR-T cell therapy clinical trials for solid tumors.
Guo J and 3 others. Front Oncol, 2025. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Challenges and breakthroughs: current landscape and future prospects of CAR-T cell therapy clinical trials for solid tumors. Papers, record 40969260. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40969260
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Challenges and breakthroughs: current landscape and future prospects of CAR-T cell therapy clinical trials for solid tumors.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References56
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34568831 | Scalable Manufacturing of CAR T cells for Cancer Immunotherapy. | Blood Cancer Discov | 2021 | https://conductscience.org/library/papers/34568831 | PubMed |
| 2 | 39537919 | Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. | Nature | 2025 | https://conductscience.org/library/papers/39537919 | PubMed |
| 3 | 1719465 | Expression of the Met/HGF receptor in normal and neoplastic human tissues. | Oncogene | 1991 | https://conductscience.org/library/papers/1719465 | PubMed |
| 4 | 35205742 | The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35205742 | PubMed |
| 5 | 39888581 | Obecabtagene Autoleucel: First Approval. | Mol Diagn Ther | 2025 | https://conductscience.org/library/papers/39888581 | PubMed |
| 6 | 32843493 | HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery. | J Immunother Cancer | 2020 | https://conductscience.org/library/papers/32843493 | PubMed |
| 7 | 27324746 | Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response. | Prostate | 2016 | https://conductscience.org/library/papers/27324746 | PubMed |
| 8 | 38822118 | The changing landscape of cancer cell therapies: clinical trials and real-world data. | Nat Rev Drug Discov | 2024 | https://conductscience.org/library/papers/38822118 | PubMed |
| 9 | 29385370 | Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29385370 | PubMed |
| 10 | 38583184 | CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. | Cancer Discov | 2024 | https://conductscience.org/library/papers/38583184 | PubMed |
| 11 | 34325726 | IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. | J Hematol Oncol | 2021 | https://conductscience.org/library/papers/34325726 | PubMed |
| 12 | 39775044 | Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. | Nat Med | 2025 | https://conductscience.org/library/papers/39775044 | PubMed |
| 13 | 28366766 | Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers. | Mol Ther | 2017 | https://conductscience.org/library/papers/28366766 | PubMed |
| 14 | 35738799 | PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages. | J Immunother Cancer | 2022 | https://conductscience.org/library/papers/35738799 | PubMed |
| 15 | 33312759 | Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial. | Oncoimmunology | 2020 | https://conductscience.org/library/papers/33312759 | PubMed |
| 16 | 35314843 | PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. | Nat Med | 2022 | https://conductscience.org/library/papers/35314843 | PubMed |
| 17 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 18 | 37377890 | Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma. | Cancer Res Commun | 2023 | https://conductscience.org/library/papers/37377890 | PubMed |
| 19 | 33824268 | CAR-T cell therapy: current limitations and potential strategies. | Blood Cancer J | 2021 | https://conductscience.org/library/papers/33824268 | PubMed |
| 20 | 38867077 | PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. | Nat Med | 2024 | https://conductscience.org/library/papers/38867077 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42827775 | In vivo CAR-T cell generation: a production-rate framework linking vector and cellular pharmacology. | Front Immunol | 2026 | https://conductscience.org/library/papers/42827775 | PubMed |
| 42814277 | Recent advancements and persisting challenges in the evolution of next generation car t cell therapy for solid malignancies: a comprehensive review. | Immunol Res | 2026 | https://conductscience.org/library/papers/42814277 | PubMed |
| 42811304 | Co-expression of non-signaling CARs enhances EGFRvIII-specific CAR T-cell cytotoxicity against head and neck squamous cell carcinoma. | BMC Cancer | 2026 | https://conductscience.org/library/papers/42811304 | PubMed |
| 42741322 | Advances in CAR-T Cell Therapy: From Structural Design Innovations to Clinical Translation Challenges. | J Cancer | 2026 | https://conductscience.org/library/papers/42741322 | PubMed |
| 42517272 | The evolution of cellular therapies in sarcoma: Breakthroughs, challenges, and future directions. | Hum Vaccin Immunother | 2026 | https://conductscience.org/library/papers/42517272 | PubMed |
| 42471452 | Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma. | Cancer Immunol Immunother | 2026 | https://conductscience.org/library/papers/42471452 | PubMed |
| 42363170 | Next-generation of mesothelin-targeted CAR-T cells secreting anti-PD-L1 scFv for potent immunotherapy against 3D patient-derived colorectal cancer organoids. | BMC Med | 2026 | https://conductscience.org/library/papers/42363170 | PubMed |
| 41802306 | Immunotherapy for microsatellite-stable colorectal cancer: overcoming resistance and exploring novel therapeutic strategies. | Ann Coloproctol | 2026 | https://conductscience.org/library/papers/41802306 | PubMed |
| 41335396 | Decoding the role of mesothelin in tumor dynamics and targeted treatment innovations. | Mol Biomed | 2025 | https://conductscience.org/library/papers/41335396 | PubMed |
Genes9
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD276 | 80381 | PubTator's text mining | https://conductscience.org/library/genes/80381 | NCBI Gene |
| CEACAM3 | 1084 | PubTator's text mining | https://conductscience.org/library/genes/1084 | NCBI Gene |
| CXADRP1 | 653108 | PubTator's text mining | https://conductscience.org/library/genes/653108 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| FOLH1 | 2346 | PubTator's text mining | https://conductscience.org/library/genes/2346 | NCBI Gene |
| IL13RA2 | 3598 | PubTator's text mining | https://conductscience.org/library/genes/3598 | NCBI Gene |
| MSLN | 10232 | PubTator's text mining | https://conductscience.org/library/genes/10232 | NCBI Gene |
| PSCA | 8000 | PubTator's text mining | https://conductscience.org/library/genes/8000 | NCBI Gene |
| ROR1 | 4919 | PubTator's text mining | https://conductscience.org/library/genes/4919 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40969260
GET https://conductscience.org/api/papers/v1/40969260/references?page=2